Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00334828 · ClinicalTrials.gov registry record · Phase 3

ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis

A Phase 3 study of Severe Sepsis, sponsored by Eisai.

Completed
Registry status
Phase 3
Development phase
2,000
Enrollment target
20
Study locations

NCT00334828 is a Phase 3 study of Severe Sepsis that has completed, run by Eisai. The registered enrollment target is 2,000 participants, below the 5,989-participant average among 9 other Severe Sepsis trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00334828, a Phase 3 study of Severe Sepsis, has completed, sponsored by Eisai.

COMPLETED
Registry status
Phase 3
Development phase
2,000 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to compare eritoran tetrasodium and placebo in patients with severe sepsis and to demonstrate a reduction of mortality from all causes.

Conditions Studied

Severe Sepsis

Interventions

  • DRUG Placebo
  • DRUG eritoran tetrasodium

Study Locations (20)

Florida

  • - Atlantis
  • - Clearwater
  • - Gainesville
  • - Miami
  • - Orlando
  • - Pensacola

California

  • - Loma Linda
  • - Marysville
  • - Orange
  • - San Diego
  • - Santa Barbara

Alabama

  • - Birmingham
  • - Mobile

Georgia

  • - Atlanta
  • - Decatur

Arizona

  • - Mesa

Colorado

  • - Denver

Connecticut

  • - New Haven

Delaware

  • - Newark

Trial Details

FieldValue
Enrollment Target 2,000 participants
Start Date 2006-06
Phase Phase 3

Sponsor

Eisai

287 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00334828

The ClinicalTrials.gov registry entry for NCT00334828 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,989-participant average among 9 other Severe Sepsis trials with a reported enrollment target (67% lower). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Severe Sepsis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00334828 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Alabama.

Frequently Asked Questions

What is clinical trial NCT00334828 about?

NCT00334828 is a clinical study titled "ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis". The purpose of this study is to compare eritoran tetrasodium and placebo in patients with severe sepsis and to demonstrate a reduction of mortality from all causes.

What is the current status of trial NCT00334828?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,000 participants. The study started on 2006-06.

What conditions does trial NCT00334828 study?

This clinical trial studies the following conditions: Severe Sepsis.

What interventions are being tested in trial NCT00334828?

The interventions under investigation include: Placebo (DRUG), eritoran tetrasodium (DRUG).

Who is sponsoring clinical trial NCT00334828?

This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00334828 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Severe Sepsis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Severe Sepsis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.